| - |
Fampridine |
Fampyra® |
For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7). |
Assessment process complete |
17th August 2012 |
 |
| 22060 |
Faricimab |
Vabysmo ® |
For the treatment of adult patients with neovascular (wet) age-related macular degeneration. |
NCPE Assessment Process Complete |
30th June 2025 |
|
| 22061 |
Faricimab |
Vabysmo ® |
For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO). |
NCPE Assessment Process Complete |
1st July 2025 |
|
| 21069 |
Fedratinib |
Inrebic® |
For the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis who are JAK inhibitor–naive or have been treated with ruxolitinib. |
Rapid Review Complete |
20th January 2022 |
|
| 23048 |
Fenfluramine (Fintepla®) |
Fintepla® |
Fenfluramine (Fintepla®) is indicated for seizures associated with Dravet Syndrome (as an add-on therapy for patients two years of age and older). |
NCPE Assessment Process Complete |
3rd July 2024 |
|
| 23051 |
Fenfluramine |
Fintepla® |
Fenfluramine (Fintepla®) is indicated for patients (two years of age and older) with Lennox-Gastaut Syndrome as an add-on therapy to other anti-epileptic medicines. |
NCPE Assessment Process Complete |
16th September 2024 |
|
| - |
Ferric maltol |
Feraccru® |
For the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients. |
Assessment process complete |
6th September 2016 |
|
| - |
Ferumoxytol |
Rienso® |
For the treatment of iron deficiency anaemia in adult patients with chronic kidney disease (CKD). |
Assessment process complete |
17th August 2012 |
|
| 24005 |
Fezolinetant |
Veoza™ |
Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. |
Awaiting full HTA submission from Applicant |
24th April 2024 |
|
| - |
Fidaxomicin |
Dificlir® |
For the treatment of CDI also known as CDAD in adult patients. Rapid Review |
Assessment process complete |
5th February 2013 |
|
| 20047 |
Filgotinib |
Jyseleca® |
As monotherapy or in combination with methotrexate for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs. |
Rapid Review Complete |
16th November 2020 |
|
| 21048 |
Filgotinib |
Jyseleca® |
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. |
Assessment process complete |
10th December 2021 |
|
| 22012 |
Finerenone |
Kerendia® |
For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. |
NCPE Assessment Process Complete |
22nd August 2023 |
|
| 23077 |
Finerenone |
Kerendia® |
Finerenone (Kerendia®) is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes (T2D) in adults. |
Rapid Review Complete |
23rd January 2024 |
|
| - |
Fingolimod |
Gilenya® |
For the treatment of highly active relapsing-remitting multiple sclerosis. |
Full Assessment Complete |
22nd September 2011 |
|
| - |
Fluocinolone acetonide intravitreal implant |
Iluvien® |
For the treatment of vision impairment associated with chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies. |
Rapid Review Complete |
1st March 2016 |
|
| 20050 |
Fluocinolone acetonide intravitreal implant |
Iluvien® |
For the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. |
Assessment process complete |
21st December 2020 |
|
| - |
Fluoride toothpaste |
Duraphat® 5,000 ppm |
For the prevention of dental caries in adolescents and adults, particularly amongst patients at risk from multiple caries (coronal and/or root caries). |
Rapid Review Complete |
7th January 2020 |
|
| - |
Fluticasone furoate/ umeclidinium/ vilantero |
Trelegy™ Ellipta™ |
For the maintenance treatment of adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA. |
Assessment process complete |
19th June 2018 |
|
| - |
Fluticasone furoate/vilanterol |
Relvar™ Ellipta™ |
For both (i) the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta-2-agonist. and (ii) for symptomatic treatment of patients with COPD with a FEV1<70% of predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy. |
Rapid Review Complete |
23rd December 2013 |
|
| - |
Follitropin delta |
Rekovelle® |
For controlled ovarian stimulation (COS) for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. |
Assessment process complete |
16th August 2017 |
|
| 23019 |
Fondaparinux |
Arixtra® |
Fondaparinux (Arixtra®) is indicated for the prevention of Venous Thromboembolic Events, treatment of Acute coronary syndrome, treatment of Superficial vein thrombosis, treatment of Deep vein thrombosis and acute Pulmonary Embolism. |
Rapid Review Complete |
12th November 2024 |
|
| 21015 |
Formoterol fumarate dihydrate, glycopyrronium, budesonide |
Trixeo Aerosphere® |
For the maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist. |
Rapid Review Complete |
30th April 2021 |
|
| 23007 |
Foslevodopa/foscarbidopa |
Produodopa® |
Foslevodopa/foscarbidopa (Produodopa®) is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. |
Rapid Review Complete |
14th March 2024 |
|
| 23018 |
Fostemsavir |
Rukobia ® |
Fostemsavir (Rukobia ®) in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. |
Rapid Review Complete |
11th March 2025 |
|
| - |
Fremanezumab |
Ajovy® |
For prophylaxis of migraine in adults who have at least four migraine days per month. |
Assessment process complete |
7th September 2020 |
|
| 24031 |
Fruquintinib |
Fruzaqla® |
For the treatment of adult patients with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF agents, and anti EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine tipiracil or regorafenib |
Rapid Review Complete |
16th September 2024 |
|
